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Abstract
Background: Stable disease (SD) has ambiguous clinical significance for patients according to the dominant
Response Evaluation Criteria in Solid Tumours (RECIST). The primary aims of the study were: (1) to clarify the clinical
significance of SD by comparing the progression-free survival (PFS) of response and SD patients with advanced
non-small cell lung cancer (NSCLC) after the first two courses of the standard first-line platinum-based
chemotherapy; (2) to explore the relationship between the percentage change in tumour size and PFS among
initial SD patients, in order to provide some guidance for clinicians in deciding continuation/termination of the
current treatment at a relative early time.
Methods: A total of 179 advanced NSCLC patients whose baseline CT image was available for review were
included in the study. Another CT image was taken in the initial assessment after chemotherapy. A comparison of
PFS between initial partial response (PR) and SD was used to determine whether significant differences exist. The
relationship between the early percentage of change in tumour size of initial SD patients and their PFS was
investigated. In addition, overall survival (OS), the secondary endpoint in this study, was investigated as well.
Results: Patients with initial PR are not significantly distinguished from those with initial SD when their PFS is
concerned (median PFS 249 days [95% confidence interval, 187-310 days] versus 220 days [95% confidence interval,
191-248 days], p > 0.05). Their median OS was 364 days (95% confidence interval, 275-452 days) for the initial PR
patients versus 350 days (95% confidence interval, 293-406 days) for the initial SD patients, which suggests no
significant difference as well p > 0.05). In addition, all the initial SD patients enjoyed similar PFS and OS.
Conclusions: Initial PR and SD enjoy similar PFS and OS for patients with advanced NSCLC. Within the initial SD
subgroup, different percentages of tumour shrinkage or increase undergo similar PFS and OS. RECIST remains a
reliable norm in assessing the effectiveness of chemotherapy for patients with advanced NSCLC before functional
assessment has been integrated into the criteria.
Background
The change of tumour size is regarded as an objective
indicator in assessing the efficiency of any anticancer
therapy. Currently, the Response Evaluation Criteria in
Solid Tumours (RECIST), which was established in
2000, and was revised in 2009, i.e. RECIST1.1, to replace
the World Health Organization (WHO) criteria for
tumour response evaluation, is widely used in evaluating
the response to anticancer treatment. Using RECIST
measurement criteria, patients in clinical treatments are
stratified into one of four groups, i.e. complete response
(CR), partial response (PR), stable disease (SD) and pro-
gressive disease (PD) on the basis of change in lesion
size [1] derived from CT scans.
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categories is to acquire optimal treatment schemes. CR
and PR indicate apparent decrease in tumour size. PD
means a significant increase in tumour size or with the
appearance of new lesions. SD is a relatively more com-
plex category, and ranges from a minor decrease to a
minor increase. It is generally accepted that a decrease in
tumour size suggests effectiveness of the current therapy
and an increase in tumour size indicates ineffectiveness.
But when it comes to replacement of the current medical
decision, only PD patients accept an alternative therapy
in clinical practice. The maintenance of SD patients on
their original treatment schemes is accepted as the norm
in routine practice, although RECIST does not provide
any reliable suggestion for clinicians to follow. Lara et al.
share the same notion by claiming that initial disease
control rate (DCR), including CR, PR and SD, is more
powerful in predicting subsequent survival than the tradi-
tional tumour response rate alone (CR and PR). Non-
progression of the disease is widely believed to have
enjoyed survival benefits from the current treatment
scheme [2]. Recently, an increasing number of experts
propose that DCR should be used to predict survival [3].
The definition of response categories in RECIST is an
arbitrary convention that is not based on any clinical
data, for it has been adapted from the earlier WHO cri-
teria on the assumption that the tumour is spherical
model [4-7]. SD, with its complex components, has long
been viewed as a controversial category with an equivo-
cal result and its clinical significance is unclear. Many
clinicians believe it is an arbitrary stratification of
change in tumour size rather than a provision of any
meaningful suggestion for clinical practice. Many physi-
cians have tried to identify the clinical significance of
SD and some claim that patients with initial SD after
their first-line chemotherapy have poorer survival out-
come and less symptomatic benefit than those with PR.
Replacement of the current treatments is strongly
recommended [8-12].
A further classification of SD research by W. De
Roock et al. found that an initial relative decrease of
more than 10% in tumour size at week 6 is associated
with clinical benefit, and is regarded as a reliable cut-off
point to predict the progression-free survival (PFS) and
overall survival (OS) in chemorefractory metastatic col-
orectal cancer (cmCRC) patients treated with cetuximab
(CTX) ± irinotecan (IRI). Thus, some SD patients have
benefited from their treatment. This finding might be
exploited in early discontinuation/crossover trials
[13-15].
Especially, with the latest development of imaging tech-
niques and the advent of targeted drugs, increasing num-
bers of patients achieve SD after biologic targeted
therapies according to RECIST, whereas functional
evaluation suggests that not all SD patients benefit
directly from their treatments [16]. The biological beha-
viour of tumour cells is rather complicated; thus, further
stratification of SD by tumour size is of great importance.
Chemotherapy is still the dominant treatment for
advanced non-small cell lung cancer (NSCLC). However,
the reality is that only a few patients with advanced
NSCLC experience tumor decrease, i.e. “radiographic
response” after standard first-line platinum-based che-
motherapy and many more patients experience SD. So,
it is very important to choose a suitable treatment regi-
men for advanced NSCLC patients who get SD in their
initial assessment after the first two courses of first-line
platinum-based chemotherapy. However, whether the
different level of SD (the percentage of tumour shrink-
age or increase) undergoes different PFS or even OS,
whether all SD patients benefit from the original treat-
ments is of great importance in current clinical practice.
PFS is believed to be a rapid and accurate indicator for
assessing the effectiveness of first-line treatment and
predicting survival benefits. It can be used as a scale for
retaining/replacing first-line treatments.
The main objectives of this study were: (1) to clarify the
clinical significance of SD by comparing the PFS of PR
and SD patients after the first two courses of chemother-
apy; and (2) to explore the relationship between the
change of tumour size, which ranges from minor decrease
to minor increase, and their PFS among the achieved SD
patients with advanced NSCLC according to RECIST in
their initial assessment after the first two cycles of first-
line platinum-based chemotherapy, to provide some gui-
dance for clinical practice at a relatively early time.
Methods
Patient Selection
Between April 2007 and November 2009, 188 patients
were enrolled and accepted medical treatment at two
hospitals: the 1st Hospital of China Medical University
and the Oncology Hospital of Liaoning Province in the
northeast of China. Male and female patients in the age
range 18 – 80 years were eligible for the research if they
met the following criteria: histologically or cytologically
confirmed with non-small cell lung cancer (NSCLC)
that is unresectable, recurrent or metastatic; no previous
adjuvant chemotherapy or recurrent metastatic NSCLC
patients who have not received adjuvant chemotherapy
for at least 6 months before the trial; at least one mea-
surable tumour lesion not located in the locus that has
received radiotherapy according to RECIST ver.1.1.
Liver metastatic lesions that had received interventional
therapy were not regarded as measurable lesions and
hollow viscous lesions were not regarded as target
lesions. The other requisites were: anticipated time of
survival of at least three months; a desirable life
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tive Oncology Group (ECOG) performance status; ade-
quate renal, hepatic, cardiac and hematologic function.
One week before enrolment in the study, the hematolo-
gic test should meet the following criteria: WBC ≥ 4.0 ×
10
9/L, ANC ≥ 2.0 × 10
9/L, HB ≥ 10 g/dL, PLT ≥ 100 ×
10
9/L, TBI, ALT, AST, ALP and Cr counts less than 1.5
times the maximal peak, and TBI, ALT, AST, ALP less
than 5 times the peak if liver metastasis occurs.
Patients were not enrolled in the study if they had
only immeasurable lesions, such as malignant pleural
effusion, ill-defined pulmonary densities and osseous
metastasis, or if their only measurable lesion had
received radiotherapy during the research; or they had
brain metastases or meningeal metastases.
The study was totally in compliance with the Declara-
tion of Helsinki, and was formally approved by the med-
ical ethics committee of the First Hospital of China
Medical University (No.200715). Each patient gave a
written informed consent before any study-related pro-
cedures were performed.
Treatments
All patients with advanced NSCLC were assigned to a
combination of platinum-based chemotherapy, i.e. NP
(vinorelbine, 25 mg/m
2 on days 1 and 8; cisplatin, 75-80
mg/m
2 on day 1), GP (gemcitabine, 1000 mg/m
2 on days
1 and 8; cisplatin, 75-80 mg/m
2 on day 1), PP (paclitaxel,
135-175 mg/m
2 on day 1; cisplatin, 75-80 mg/m
2 on day
1) or TP (docetaxel, 75 mg/m
2 on day 1; cisplatin, 75-80
mg/m
2 on day 1) treatment schemes according to their
own conditions and wishes. Each patient received 4-6
courses of chemotherapy, and each course lasted 3
weeks. An assessment was made after every 2 courses of
chemotherapy. Patients with PD were excluded from this
group and received a different treatment regimen.
Dosage Adjustment Scheme
Adverse events were graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
toxicity scale. If hematologic toxicity III or greater
occurred, the dosage for the next cycle was decreased to
75-85% of the original dosage or the next course of treat-
ment was postponed by 1 or 2 weeks. If hematologic
toxicity III or greater remained, or a fever from combined
severe infection and granulocytopenia IV occurred, the
planned treatment was terminated. If non-hematologic
toxicity (except trichomadesis) III or greater occurs, the
dosage for the next course was adjusted to 75-85% of the
original dosage. If cardiotoxicity II - IV occurred, treat-
ment was discontinued. Throughout chemotherapy, adju-
vant medicine such as antanacathartic, colony-
stimulating factor and diphosphonate were given to
reduce adverse events when necessary.
Image Data Collection and Study
Each patient had a base-line check within one month
before their first-line chemotherapeutic treatment
started. To ensure the credibility of the study, images of
measurable lesions were obtained by the qualified radiol-
ogists through CT or Spiro-CT scans. Subsequent images
were obtained by the same radiologist after the first 2
courses of chemotherapy for each patient. To minimize
variation between operators, all measurements of the
images were done at the same anatomic level and orien-
tation by an independent qualified radiologist. In contrast
with the base-line images, any change in the size of target
lesions was calculated according to RECIST ver.1.1.
Patients with an increase of 20% or more in lesion size or
those with new lesions were regarded as having PD and
were excluded from the study. Patients with a change of
lesion size ranging from an increase of <20% to a
decrease of <30% and with no new lesion were stratified
as having SD. Patients with a 30% or greater decrease in
the target lesion were regarded as achieving PR. Patients
with disappearance of the lesion were stratified as achiev-
ing CR. For those with SD, the percentage of change in
tumour size has been recorded for further study.
Follow-up Visit
A follow-up visit was given to each patient who
achieved CR, PR and SD. The assessment process was
repeated every 2 courses until the end of the che-
motherapy, or the aggravation of the disease, and after
that, every 2 months until the progression of the disease
or death occurred. This kind of service could be pro-
vided to meet a patient’s need at any time. The percen-
tage of change in size of target tumours and the PFS
were the main contents for a follow-up visit.
Statistical Analysis
SPSS13.0 software was used for all statistical analysis.
The correlation between the change in size of target
lesions before and after the first two courses of che-
motherapy and their PFS and OS were calculated.
According to the RECIST ver.1.1, the sum of the longest
dimension of all the target lesions was calculated for
each patient to provide the baseline before treatment.
The same measurements and calculation were done
after the first two courses of chemotherapy to obtain
the initial assessment sum. The change ratio of target
lesions was calculated as:
() / Assessment sum Baseline sum Baseline sum −
The primary endpoint was PFS, which is calculated
from the date of first treatment to disease progression
(local or metastatic) or death; and the secondary end-
point was OS, which is calculated from the date of first
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Kaplan-Meier curve was used to describe PFS and OS,
and a log-rank test was used to compare the PFS and
OS of each category defined according to the percentage
r e d u c t i o ni nt u m o u rs i z ei . e .≥30% [PR], ≥25%, ≥20%,
≥15%, ≥10%, ≥5%, and ≥0%.The c
2 test was used for
qualitative data analysis, and the Kruskal-Wallis test or
variance analysis was used to analyse the quantitative
data. Variables included in the multivariate analysis
were age, sex, grade of the disease, ECOG performance
status, and weight loss. P < 0.05 was set as the level of
statistical significance.
Results
Distribution of Response Categories and Patient
Characteristics
Altogether, 188 patients were enrolled in the trial but 9
withdrew after completing their first cycle of che-
motherapy. (Four refused to accept the treatment, one
died from myocardial infarction, three received radio-
therapy for the their target lesions, and one experienced
PD with osseous metastasis.) The remaining 179
patients with inoperative NSCLC had the initial assess-
ment after the first two courses of first-line platinum-
based chemotherapy: 37 achieved PR and 117 were
regarded as SD and these 154 patients (PR + SD) were
eligible for the final analysis (Figure 1). The remaining
25 had PD and no CR according to RECIST. Table 1
summarizes the characteristics of the patients included
in this analysis. The median age of the patients when
enrolled into the study was 57 years (range 26 - 77
years), with 38% > 60 years. A total of 92 males (60%)
were eligible for the analysis. The vast majority of
patients (63%) had stage IV disease, 64 patients (42%)
reported a weight loss of ≥5%, and the majority of
patients had an ECOG performance status of 0 or 1.
Distribution of Change in Tumour Size of Initial SD
Patients
Among the patients with SD derived from the assess-
ment after the first two courses of first-line platinum-
based chemotherapy there was a decrease of tumour
size of 25-30% for 17, 20-25% for 18, 15-20% for 16, 10-
15% for 12 and 5-10% for 8 and 0-5% for 29. The
increase of tumour size in the other patients was <20%.
The result is depicted in waterfall plots (Figure 2).
Comparison of PFS and OS of Patients with Initial PR and
SD
The patients were divided into two subgroups (PR and
SD) after two courses of treatment. Careful examination
found no statistically significant difference of patient
characteristics between the two groups, i.e. baseline
characteristics were well balanced between PR and SD
(Table 2). The median PFS was 249 days (95%
Figure 1 Consort diagram of patient denominator.P Rp a r t i a l
response; SD stable disease; PD progressive disease.
Table 1 Patient Characteristics
Characteristics Patients(PR + SD)
(n = 154)
Age, years
Median 57
Range 26-77
Sex
Female 62
Male 92
Stage
IIIB 57
IV 97
ECOG performance status
08 4
17 0
Weight loss ≥5%
Yes 64
No 90
PR Partial Response; SD Stable Disease; ECOG Eastern Cooperative Oncology
Group.
Figure 2 Initial evaluation among SD patients in waterfall plot
distribution (range -29% to +19.9%). SD stable disease.
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Page 4 of 11confidence interval, 187-310 days) for the 37 patients
with PR and 220 days (95% confidence interval, 191-248
days) for the 117 patients with SD. The log-rank test
found no significant difference of PFS (P = 0.991)
between the PR and SD subgroups (Figure 3a). The total
follow-up time ranges from 2 months to 40 months, and
by the end of the last follow-up time (Sept, 2010), 22 is
still alive (5 PR, 17 SD). The median OS was 364 days
(95% confidence interval, 275-452 days) for the PR
patients and 350 days (95% confidence interval, 293-406
days) for the SD patients respectively. The log-rank test
found no significant difference of OS (P = 0.861)
between the PR and SD subgroups (Figure 3b).
Relationship between Change in Target Lesion Size and
PFS and OS among Initial SD Patients
The response rate varied significantly according to the
definition of “response rate” (Table 3). The median PFS
of patients with ≥25%, ≥20%, ≥15%, ≥10%, ≥5% or ≥0%
decrease in tumour size was 289 days, 270 days, 242
days, 225 days, 221 days or 221 days, respectively; the
median OS was 377 days, 412 days, 385 days, 387 days,
385 days and 350 days, respectively. The P value asso-
ciated with the log-rank test comparing the PFS and OS
of responding patients with that of non-responding
patients using different definitions of response are
s h o w ni nT a b l e3a n dF i g u r e4a n dF i g u r e5 .A si n d i -
cated, no significantly better cut-off point, i.e. optimal
percentage of decrease in tumour size, was found in pre-
dicting the PFS and OS of the patients with SD. In addi-
tion, among SD patients, those with an initial decrease
of 30-20% in tumour size were not significantly distin-
guishable (P > 0.05) from those with an initial increase.
Multivariate analysis included factors such as sex, age,
weight loss, ECOG performance status, and stage of dis-
ease, which might have a potential effect on prognosis
Table 2 Patient Characteristics
Response after 2 courses of platinum-based chemotherapy
PR (n = 37) (%) SD (n = 117) (%) P
Age, year, median 56 57 0.286
Sex, %
Female 15(41%) 47(40%) 0.968
Male 22(59%) 70(60%)
Stage, %
IIIB 13(35%) 44(38%) 0.786
IV 24(65%) 73(62%)
ECOG performance status, %
0 25(68%) 59(50%) 0.068
1 12(32%) 58(50%)
Weight loss ≥5%, % 14(38%) 50(43%) 0.598
PR Partial Response; SD Stable Disease; ECOG Eastern Cooperative Oncology Group.
Figure 3 Comparison of PFS (a) and OS (b) between PR and SD. PR partial response; SD stable disease; PFS progression-free survival; OS
overall survival.
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weight loss of ≥5% was relatively worse for predicting
PFS (P < 0.05). Cox regression analysis showed that
other prognostic factors like age, sex, stage of disease,
the percentage of change in target lesion size of patients
with SD derived from the initial assessment after the
first two courses of chemotherapy are not associated
with PFS (P > 0.05)
Discussion
OS has long been considered to be the most important
indicator of clinical efficacy endpoints for any treatment
regimen. However, OS requires prolonged follow-up,
and is often affected significantly by other factors, such
as the effects of second-line and subsequent therapies
and so it cannot be used as a scale for adjusting first-
line treatments. PFS, a biological indicator, can be
applied to measure tumour burden directly. Especially,
PFS can swiftly and accurately indicate the survival ben-
efit of the first-line therapy, which enables clinicians to
modify their treatment projects as soon as possible.
Recent research has found that PFS is correlated posi-
tively with OS and it has been accepted as a surrogate
for OS in advanced cancer [17-22].
RECIST, which is based on morphological features of
the tumour, has been adopted as a norm for clinical
trials. According to RECIST, patients who demonstrate
a response often continue with their treatment proto-
cols, and termination of the original therapeutic regimen
and replacement with another has been considered for
those who do not respond. In clinical practice, however,
it is common to find that some patients demonstrate a
dramatic response to chemotherapy, but they might not
have any survival advantage when compared with the
patients who do not respond [23,24]. Other patients
who demonstrate SD or a minimal disease progression
might end up with extended long-term survival.
Focusing on this phenomenon, Katherine R et al.
reached the conclusion that in their study of patients
with advanced NSCLC there was no significant differ-
ence between the initial response categories of PR and
SD with respect to overall survival [25]. In addition,
Lara et al. suggested that SD enjoys equal survival signif-
icance with CR and PR. They claim that DCR, com-
p o s e do fC R ,P Ra n dS D ,i sm o r ep o w e r f u lt h a n
response i.e. CR and PR alone in predicting the overall
survival of patients with advanced NSCLC [2]. Some
experts suggest that SD might represent a potential sur-
vival benefit of chemotherapy. Therefore, the distinction
between SD and PR might be of no practical importance
[26,27].
Similar to the studies mentioned above, the results of
the current study suggest that tumour shrinkage in the
CT image derived from the initial treatment-assessment
after the first 2 courses of first-line chemotherapy, i.e.
early radiographic response in patients with advanced
NSCLC is not positively related with their PFS and OS,
thus, it cannot predict the outcome of chemotherapy.
That is to say, patients with PR and SD derived from
their initial assessment have similar PFS and OS. So, PR
and SD enjoy the same clinical significance in predicting
PFS or even OS according to RECIST. It is clear that
patients with SD have also benefited from the continua-
tion of the original treatment. The creative point is that
this prospective study adopts treatment schemes with
similar effectiveness to reduce any possible bias, and
PFS as the end point, which can reflect effectiveness of
their first-line treatment at a relatively early time, thus
early adjustment of treatment is likely to be adopted.
SD is often used as a decisive point in treatment man-
agement in clinical research, but it is regarded as a cate-
gory with much controversy. Continuation of the
original treatment for the NSCLC patients with initial
SD has been generally adopted. But the notion that
Table 3 Variable Response Criteria
Definition of responder Group No Median PFS(95%CI) P Dead No. Median OS(95%CI) P
≥25% Reduction in tumour Nonresponder 100 218(176-259) 0.319 86 335(261-408) 0.240
Responder 17 289(225-352) 14 377(338-415)
≥20% Reduction in tumour Nonresponder 82 218(171-264) 0.874 71 323(276-369) 0.168
Responder 35 270(181-358) 29 412(328-495)
≥15% Reduction in tumour Nonresponder 66 200(149-250) 0.937 57 323(279-366) 0.323
Responder 51 242(190-294) 43 385(309-460)
≥10% Reduction in tumour Nonresponder 54 198(127-268) 0.948 47 320(268-371) 0.334
Responder 63 225(176-273) 53 387(320-453)
≥5% Reduction in tumour Nonresponder 46 218(147-289) 0.789 40 320(272-367) 0.362
Responder 71 221(177-265) 60 385(317-452)
≥0% Reduction in tumour Nonresponder 17 198(105-291) 0.913 15 323(195-450) 0.448
Responder 100 221(193-249) 85 350(286-413)
95% CI indicates 95% Confidence Interval; PFS Progression-free Survival; OS Overall survival.
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plexity of SD should be taken into careful consideration.
Thus, a suggestion for further classification of SD is
needed urgently for an alternative therapy at an early
time. Certain further stratification of SD studies claim
that an initial decrease in tumour size has little to do
with overall survival, and no particular percentage of
r e d u c t i o ni nt u m o u rs i z eh a sb e e nf o u n dt ob e
Figure 4 Relationship between the changing ratio in size of target lesion and PSF among SD patients. Comparison of PFS of SD patients
stratified by a reduction in target lesion size of (a) 25%, (b) 20%, (c) 15%, (d) 10%, (e) 5%. and (f) 0%. SD stable disease; PFS progression-free survival.
He et al. BMC Cancer 2010, 10:681
http://www.biomedcentral.com/1471-2407/10/681
Page 7 of 11correlated optimally with survival for patients with
advanced NSCLC [25]. However, those studies do have
several limitations, such as variation of treatment and
their endpoint OS requires a long period of follow-up.
Subsequent treatments might seriously interfere with
OS, which cannot be regarded as evidence to guide
early adjustment of first-line therapy. The current study
uses similar treatment schemes and PFS as the primary
Figure 5 Relationship between the changing ratio in size of target lesion and OS among SD patients. Comparison of OS of SD patients
stratified by a reduction in target lesion size of (a) 25%, (b) 20%, (c) 15%, (d) 10%, (e) 5%. and (f) 0%. SD stable disease; OS overall survival.
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Page 8 of 11end point. By further classifying SD patients, this study
indicates that no optimal percentage change in tumour
size associated with PFS exists in patients with NSCLC.
All SD patients enjoy similar PFS and OS, which implies
that they might benefit from their original treatments.
This study further verifies that the current clinical norm
of continuation of treatments in patients with NSCLC
who have SD after two cycles of first-line platinum-
based chemotherapy is the standard treatment.
As noted above, this study is based solely on morpho-
logical features, i.e. tumour size, which cannot reflect
tumour cell viability in advanced NSCLC precisely. A
study conducted by Liu-Jarin et al. also supports the
notion that no correlation between tumour viability and
radiographic response has been found after examination
of the histological appearance of tumours after neoadju-
vant therapy [28]. Since lung cancers are typically het-
erogeneous, composed of both cancer cells and a host
inflammatory response in various proportions. Measur-
ing tumour size by anatomic imaging studies alone pro-
vides only a macroscopic description of the lesion [29].
It is hard, sometimes even unlikely, to distinguish
tumour from inflammatory response by a chest CT
scan. For instance, a reduction in tumour cells but an
increase in inflammatory component might seem equal
to an increase in tumour cells but a decrease in inflam-
matory component as judged from early radiographic
response alone. A similar phenomenon has been noted
in the evaluation of gastrointestinal stromal cell tumours
(GISTs). The treatments of GISTs with chemotherapeu-
tic agents rarely results in a reduction of overall tumour
size, but decreases the tumour cell burden, which is
undetectable by macroscopic measurement alone [30].
Histological studies of treated NSCLC have demon-
strated that the percentage of residual viable tumour
cells is a reliable predictor of survival, and that many
tumours that exhibit little change in overall size might
actually have regressed significantly [31,32]. Recent ima-
ging developments based on both tumour morphology
and tumour function make correct, precise, and repro-
ducible measurement available. In addition, it has been
proved that functional response appears relatively earlier
than radiographic response [33-35].
RECIST cannot accurately reflect the change of viabi-
lity of a tumour cell. This is especially true with the
occurrence of targeted therapy. Many studies indicate
that after functional evaluation, some initial SD patients
benefit greatly from their treatments, while some others
should use an alternative therapy as early as possible.
Just as Choi et al. suggest in their study that more sensi-
tive criteria, a 10% decrease in size or a 15% decrease in
density on contrast-enhanced CT, have been shown to
be more accurate in the assessment of treatment efficacy
and the prediction of survival in patients with GIST
[16]. The application of PET, which can predict survival
[36], to the initial SD subgroup might attain a functional
response rather than an anatomical response. PET can
provide some early guidance in clinical practice. Some
published data indicate that the percentage [18F]fluoro-
deoxyglucose uptake after one and three courses of
induction chemotherapy predicts survival in stage IIIA-
N2 patients [37]. Still, integration of tumour biomarkers
into standard response criteria might be useful in the
evaluation of NSCLC because tumour biomarkers have
been proven meaningful in determining tumour biology,
viability in NSCLC, and predicting outcome in patients
with early stage lung cancer [38,39]. Future studies
could integrate functional evaluation into the initial SD
subgroup, thus might provide some early guidance on
continuation/replacement of chemotherapy. It might be
more important to individualize treatment for initial SD
patients with advanced NSCLC as early as possible to
optimize the effectiveness of the treatment.
Conclusion
Firstly, non-progression, i.e. PR, SD derived from the
initial radiographic responsea f t e rt h ef i r s tt w oc o u r s e s
of platinum-based chemotherapy enjoys similar PFS and
OS for patients with advanced NSCLC; secondly,
focused on the SD subgroup, different levels of SD (dif-
ferent percentages of tumour shrinkage or increase)
undergo similar PFS and OS; lastly, RECIST remains a
reliable norm in assessing the effectiveness of che-
motherapy for patients with advanced NSCLC and
instructing clinical medication before any functional
assessment has been imported into the criteria. Hope-
fully, further studies will integrate functional assessment,
such as contrast-enhanced CT and PET/CT, tumour
biomarkers into the RECIST criteria, thus are likely to
c r e a t eam o r er e l i a b l er e s p o n s ec r i t e r i af o ra d v a n c e d
NSCLC in the future.
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